Wellington Management Group LLP Grows Stock Holdings in Omnicell, Inc. $OMCL

Key Points

• Wellington Management Group LLP increased its stake in Omnicell, Inc. by 52.6% during the first quarter, owning approximately 1.06% of the company, with total shares amounting to 496,680.
• Omnicell reported earnings of $0.45 per share for the latest quarter, surpassing the consensus estimate of $0.30, and recorded revenues of $290.56 million, which were above expectations.
• Analysts have mixed ratings on Omnicell, with a consensus price target of $46.71, as four analysts rated it a "Buy" and three a "Hold".

Wellington Management Group LLP boosted its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 52.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 496,680 shares of the company's stock after purchasing an additional 171,116 shares during the period. Wellington Management Group LLP owned about 1.06% of Omnicell worth $17,364,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in OMCL. Johnson Financial Group Inc. acquired a new stake in Omnicell in the 4th quarter valued at approximately $37,000. Point72 Hong Kong Ltd acquired a new stake in Omnicell in the 4th quarter valued at approximately $101,000. Corton Capital Inc. acquired a new stake in Omnicell in the 4th quarter valued at approximately $208,000. Caption Management LLC acquired a new stake in Omnicell in the 4th quarter valued at approximately $223,000. Finally, New Age Alpha Advisors LLC acquired a new stake in Omnicell in the 1st quarter valued at approximately $233,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on OMCL shares. Benchmark decreased their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wells Fargo & Company raised their price target on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Piper Sandler decreased their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Stock Down 2.1%

Shares of Omnicell stock traded down $0.69 during trading on Monday, hitting $32.59. 595,171 shares of the stock were exchanged, compared to its average volume of 569,766. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 65.18, a price-to-earnings-growth ratio of 7.12 and a beta of 0.82. The firm's 50-day moving average price is $30.15 and its 200 day moving average price is $31.45. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.